Anti-Glucosylceramidase beta (GBA) Rabbit Polyclonal Antibody for WB and ELISA - P04062

Core Product Specifications and Parameters

Biological Background: Glucosylceramidase beta (GBA) Function and Localization

• Lysosomal acid glucosylceramidase (GBA) hydrolyzes glucosylceramide (GlcCer) into ceramide and glucose, playing a central role in complex lipid degradation and membrane turnover. Related references: PMID:15916907 | PMID:24211208 | PMID:32144204 | PMID:27378698
• Through ceramide production, GBA participates in the PKC-activated salvage pathway of ceramide formation. Related references: PMID:19279011
• GBA catalyzes the glucosylation of cholesterol via transglucosylation, using GlcCer as a glucose donor, with preference for GlcCer containing mono-unsaturated fatty acids. Related references: PMID:24211208 | PMID:26724485 | PMID:32144204
• It can also hydrolyze cholesteryl 3-beta-D-glucoside to glucose and cholesterol. Related references: PMID:24211208 | PMID:26724485 | PMID:39395789
• In vitro, GBA hydrolyzes galactosylceramides and transfers galactose between GalCer and cholesterol, albeit with lower activity than for GlcCer. Related references: PMID:32144204
• Xylosylceramide is a poor substrate for hydrolysis but serves as a good xylose donor for transxylosylation to form cholesteryl xyloside. Related references: PMID:33361282
• Localizes to the lysosome membrane, consistent with its role in lysosomal sphingolipid metabolism.
• Mutations in GBA are linked to Gaucher disease, the most common lysosomal storage disorder, and are a strong genetic risk factor for Parkinson disease.

Experimental Guidance and Technical Tips

• The immunogen spans amino acids 40-250 of the human GBA sequence (NP_000148.2), corresponding to a region within the mature lysosomal protein. Confirm immunoreactivity in relevant human cell or tissue lysates.
• For Western blot, a band near 60 kDa is expected. Reduce and denature samples thoroughly, and use a suitable blocking buffer to minimize background.
• In ELISA, titrate the antibody against the recombinant immunogen or native protein to determine optimal coating and detection concentrations.
• Validate detection in model systems reflecting GBA-related biology (e.g., fibroblasts, neuronal cells) and consider activity modulation conditions (e.g., inhibitor treatment).

CamelBio: Your One-Stop Sourcing Bridge

CamelBio connects diagnostic developers and researchers with reliable IVD raw materials, technical services, and consulting. This anti-GBA polyclonal antibody supports immunodetection of glucosylceramidase in sphingolipid metabolism studies and Gaucher/Parkinson’s disease research. Beyond individual antibodies, CamelBio offers validated antibody pairs, optimized monoclonal/polyclonal reagents, bulk ancillary materials, and rare-target sourcing to streamline your project from concept to clinic.